Jefferson Kinney

Jefferson Kinney Headshot
Download High-Res Photo
Request as Speaker
Request as Media Expert
Founding Chair, Department of Brain Health
Expertise: Behavioral neuroscience, Alzheimer's disease, Schizophrenia, Learning and memory systems

Biography

Jefferson Kinney is the founding chair of the department of brain health in the Kirk Kerkorian School of Medicine at 51ԹϺ. Kinney investigates neurodegenerative disorders, including Alzheimer’s disease, vascular dementia, and Parkinson's disease, with a focus on cellular and molecular changes in the brain that underlie these disorders. 

His current work includes investigating the role of several risk factors associated with Alzheimer’s disease and subtle changes in cell function, including interactions between diabetes and inflammation in the brain throughout the onset and progression of the disease. As part of this work, Kinney collaborates with the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. 

Earlier in his career, Kinney completed an Intramural Research Training Fellowship with the National Institute of Mental Health and the Helen Dorris Fellowship in schizophrenia research at The Scripps Research Institute.

Education

  • B.S., Psychology, Colorado State University
  • M.S., Experimental Psychology, Colorado State University
  • Ph.D., Behavioral Neuroscience, Colorado State University

Search For Other Experts On

health & medicine, psychology & human behavior

Jefferson Kinney In The News

Alzforum
BACE1, aka β-secretase, is infamous for its fateful snip of amyloid precursor protein that leads to the production of Aβ peptides. Yet this might not be the only way BACE1 eggs on Alzheimer’s pathogenesis. According to a study published February 26 in Neuron, the enzyme also cleaves protein subunits off GABAAR, a receptor that transmits inhibitory currents responsible for reining in neuronal activity.
KJZZ
On Sunday, the Alzheimer’s Association kicks off its international conference and there’s already buzz about a blood test that is between 85% and 90% accurate in identifying Alzheimer’s disease. Having an easy blood test could be game changing. Right now, the only way to confirm an Alzheimer’s diagnosis is with a costly PET scan or an invasive spinal puncture.
P.B.S.
June is Alzheimer’s Awareness Month. We visit Cleveland Clinic Lou Ruvo Center for Brain Health to meet three people at the forefront of researching, patient advocacy, and treatment. They share what medications are currently available for patients and what they are learning about the disease. They also share information for the many people caring for a loved one with Alzheimer’s disease.
K.N.P.R. News
Right now, Nevada has the third-fastest rate of growth for Alzheimer’s disease. Between now and 2025, the number of Nevadans with dementia is expected to grow almost 31% from 49,000 to 64,000.
All Jefferson Kinney In The News

Articles Featuring Jefferson Kinney

On the Forefront of Alzheimer's Disease Research
From left to right: Dean Marc J. Kahn, Dr. Jefferson Kinney, Dr. Kate Zhong, Dr. Jeffrey Cummings, and Dr. Mark Guadagnoli at the “Brain Health Frontiers: Tackling Alzheimer's Together” panel discussion.
Campus News | February 18, 2025

The 'Brain Health Frontiers: Tackling Alzheimer's Together' panel discussion highlighted the revolutionary research the Department of Brain Health is conducting to fight Alzheimer’s disease.

51ԹϺ Newsmakers 2024: May and June
Josh Hawkins, 51ԹϺ
Campus News | July 3, 2024

News highlights featuring 51ԹϺ students and staff who made (refreshing) waves in the headlines.

All Articles Featuring Jefferson Kinney